TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2024

Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM).

Sehhoon Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.